Annexon Inc. (ANNX) carries a Roarable Rating of D- (Sell) with 40/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.
As of 2026-11-01, Annexon Inc. (NASDAQ: ANNX) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 40/100 at a spot price of $4.01 (-0.74% 1D, market cap $760.2M). Pillar breakdown: Fundamental Cash Engine 6/20, Institutional 13F & Options Flow 9/20, Executive Insider Alignment 10/20, FRED Macro Regime Fit 12/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, ANNX ranks #632 in composite RQD confidence.
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), ANNX carries a Roarable D- (40/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, ARDX (Ardelyx Inc.) holds a D- grade (35/100 RQD, P/E N/A, ROIC -32.7%, cap $772.5M) and COLL (Collegium Pharmaceutical Inc.) posts a B grade (72/100 RQD, P/E 12.4x, ROIC 85.0%, cap $782.3M). Among the 5-stock peer group, COLL leads on earnings multiple (12.4x) while COLL leads on capital efficiency (85.0% ROIC).
Per ANNX's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001528115), Annexon Inc. generated $0 in revenue, -$206.7M in net income, and -$186.5M in free cash flow against $277.6M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
FRED Regime × Technicals: 32% of 52W Range • RSI-14 at 52.4 (NEUTRAL RANGE)
Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 2/9
Dilution Drag (+2.48% YoY Shares) & executive Form 4 sales trim 16 pts from alignment
While ANNX currently carries a cautious 40/100 (D-) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.
Established market leader in Health Care with deep daily trading liquidity.
Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($4.20) and Max Pain ($4.21) forces dealer call-delta covering toward $7.54.
Forensic Repair Trigger: Halting share dilution (Dilution Drag (+2.48% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.
Annexon Inc. (ANNX) slipped -0.74% to $4.01, trading at 32% of its 52-week range ($2.54 – $7.18). Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.
BRISBANE, Calif., Oct. 28, 2026 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a biopharmaceutical company advancing the next generation platform of targeted immunotherapies aimed at neuroinflammatory diseases that im
Company management will highlight the Phase 3 ARCHER II clinical trial design, patient demographics and communication strategy for the anticipated 15-month and 24-month results beginning in Q4 2026. The Company will
Analysts upgraded Global-E and raised Annexon’s target; targets fell for Truist, Ameriprise, Lyft, A.O. Smith and Hudson Pacific.
HC Wainwright & Co. analyst Ananda Ghosh maintains Annexon (NASDAQ:ANNX) with a Buy and raises the price target from $14 to $25.
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
No active Ellis Vennor swing setup published on ANNX today. View full Setup Ledger →
No direct multi-tier Butterfly edges indexed yet for ANNX. Explore sector supply chains on /butterfly.
Across 1016 tracked Health Care securities in the Roarable RQD universe, Annexon Inc. (ANNX) ranks #632 by composite RQD confidence (40/100, grade D-) and #393 by equity capitalization ($760.2M). Within this direct 5-issuer industry benchmark cohort, COLL leads on earnings valuation at 12.4x trailing P/E, while COLL leads on capital efficiency and profitability with 85.0% ROIC and 59.3% gross margin. COLL currently holds the highest overall quantitative score in the immediate peer group at 72/100 (B) compared with ANNX at 40/100 (D-).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| ANNX
ACTIVE
Annexon Inc. | D- | 40/100 | — | — | -35.0% | -0.74% | $760.2M | Benchmark Subject |
| ARDX Ardelyx Inc. | D- | 35/100 | — | 90.3% | -32.7% | 0.00% | $772.5M | /ardx-vs-annx → |
| COLL Collegium Pharmaceutical Inc. | B | 72/100 | 12.4x | 59.3% | 85.0% | +3.44% | $782.3M | /coll-vs-annx → |
| HELP Helus Pharma Inc. | D | 49/100 | — | — | — | -1.83% | $782.5M | /help-vs-annx → |
| SGMT Sagimet Biosciences Inc. (Series A) | E | 34/100 | — | — | -35.0% | -2.89% | $735.7M | /sgmt-vs-annx → |
In its most recent audited fiscal period (FY2025, filed 2025-12-31), Annexon Inc. (ANNX) reported GAAP revenue of $0 (N/A vs. FY2024 revenue of $0 ) , GAAP net income of -$206.7M, operating cash flow of -$186.4M, and free cash flow of -$186.5M (-58.0% YoY). On the balance sheet, ANNX closed FY2025 with $277.6M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 2/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-12-31 | $0 | -$206.7M | -$186.4M | -$186.5M | $277.6M | — |
| FY2024 (FY) | 2024-12-31 | $0 | -$138.2M | -$118.0M | -$118.0M | $350.1M | — |
| FY2023 (FY) | 2023-12-31 | $0 | -$134.2M | -$121.1M | -$121.1M | — | — |
As of 2026-11-01, Annexon Inc. (NASDAQ: ANNX) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 40/100 at a spot price of $4.01 (-0.74% 1D, market cap $760.2M). Pillar breakdown: Fundamental Cash Engine 6/20, Institutional 13F & Options Flow 9/20, Executive Insider Alignment 10/20, FRED Macro Regime Fit 12/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, ANNX ranks #632 in composite RQD confidence.
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), ANNX carries a Roarable D- (40/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, ARDX (Ardelyx Inc.) holds a D- grade (35/100 RQD, P/E N/A, ROIC -32.7%, cap $772.5M) and COLL (Collegium Pharmaceutical Inc.) posts a B grade (72/100 RQD, P/E 12.4x, ROIC 85.0%, cap $782.3M). Among the 5-stock peer group, COLL leads on earnings multiple (12.4x) while COLL leads on capital efficiency (85.0% ROIC).
Per ANNX's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001528115), Annexon Inc. generated $0 in revenue, -$206.7M in net income, and -$186.5M in free cash flow against $277.6M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
ANNX last traded at $4.01 (-0.74% on volume of 3,285,004 shares), positioning the stock -4.52% below its 50-day simple moving average ($4.20) and -23.18% below its 200-day simple moving average ($5.22). Across its 52-week range of $2.54 to $7.18, ANNX sits at the 31.7% percentile with a 14-day RSI of 52.4 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($3.51 to $4.51).
Why ANNX Stock slipped -0.74% Today — RQD Quant Desk Flash. Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.
To protect compute speed and zero-delay Cboe BZX data quality for active members, our current $9.95/month Roarable Pro cohort is 100% full. Join the priority waiting list below and we will notify you the moment the next batch of Pro accounts opens (and lock in your $9.95/mo rate).
Link your personal ChatGPT, Claude Desktop, or Cursor via Roarable's Model Context Protocol (`mcp.roarable.com`) to query all 5,289 stocks, inspect Butterfly supply chains, and trade your `$100K Arena` account.
Interrogate SEC 10-K/10-Q filings on demand and ask custom ticker, valuation, or short-thesis questions directly to any of our 8 specialized AI Quant Analysts.
Command our AI agents to sort and sift 5,289 stocks by custom formulas, follow multi-indicator technical & cash-flow setups, and send you instant Email/SMS breakout & downgrade alerts.
Unlock sub-second Cboe BZX streaming quotes, pre-market/after-hours delta scanners, instant SEC Form 4 insider cluster alerts, and unlimited portfolio stress-testing.
All 8 Roarable Analysts (Mara Quenwick, Devon Kess, Gideon Vane, Eliott Vance, Sorel Thorne, Corin Hale, Tessa Rane, and Felix Orven) are proprietary AI Quant Analysts and automated algorithmic specialists — not human financial advisors, fiduciaries, or registered broker-dealers. While one-to-many daily stock ratings and briefings are free, custom 1-on-1 Q&A, custom AI sifting/indicator alert agents, and personal ChatGPT/Claude MCP connections consume dedicated per-user compute and require a $9.95/month Roarable Pro membership. All AI outputs are for educational and research purposes only and never constitute individualized investment advice.
Enter your Google email below for instant 1-step account activation, daily A–E stock rating alerts, and immediate access to your $100,000.00 Paper Trading Arena account.